Currently out of the existing stock ratings of Swayampakula Ramakanth, 612 are a BUY (96.23%), 23 are a HOLD (3.62%), 1 are a SELL (0.16%).

Swayampakula Ramakanth

Work Performance Price Targets & Ratings Chart

Analyst Swayampakula Ramakanth, currently employed at HC WAINWRIGHT, carries an average stock price target met ratio of 47.17% that have a potential upside of 51.8% achieved within 232 days.

Swayampakula Ramakanth’s has documented 1,162 price targets and ratings displayed on 86 stocks. The coverage is on Healthcare, Consumer Cyclical, Technology, Energy sectors.

Most recent stock forecast was given on PYXS, Pyxis Oncology at 18-Aug-2026.

Wall Street Analyst Swayampakula Ramakanth

Analyst best performing recommendations are on AEMD (AETHLON MEDICAL).
The best stock recommendation documented was for ABSI (ABSCI CORP) at 11/15/2023. The price target of $4 was fulfilled within 41 days with a profit of $2.6 (185.71%) receiving and performance score of 45.3.

Average potential price target upside

of $355.5 (77.04%) on TCRT (ALAUNOS THERAPEUTICS).
of $43 (57.15%) on TARA (PROTARA THERAPEUTICS).
of $35.09 (47.05%) on NUVL (NUVALENT).

EKSO Ekso Bionics Holdings PGEN Precigen TRIL Trillium Therapeutics VSTM Verastem BCAB Bioatla BCYC Bicycle Therapeutics Ltd CALA Calithera Biosciences CDXS Codexis HARP Harpoon Therapeutics HOOK Hookipa Pharma ITOS Iteos Therapeutics MDXG MiMedx Group OCGN Ocugen PLSE Pulse Biosciences DCTH Delcath Systems ECOR Electrocore LLC MDNA Medicenna Therapeutics Corp PSNL Personalis SURF Surface Oncology VOR Vor Biopharma XFOR X4 Pharmaceuticals CORT Corcept Therapeutics MDWD Mediwound Ltd ONCR Oncorus IMGN ImmunoGen AFMD Affimed NV ALXO Alx Oncology Holdings ASXC Asensus Surgical CELU Celularity EDAP EDAP TMS SA INAB In8bio IPA Immunoprecise Antibodies Ltd LPTX Leap Therapeutics RWLK Rewalk Robotics Ltd SRGA Surgalign Holdings VCEL Vericel Corp Ord ABSI Absci Corp AVGR Avinger IPHA Innate Pharma JANX Janux Therapeutics TCRT Alaunos Therapeutics ATEC Alphatec Holdings AVEO AVEO Pharmaceuticals CASI CASI Pharmaceuticals CLRB Cellectar Biosciences PSTI Pluristem QSI QuantumSi JNCE Jounce Therapeutics KIN Kindred Biosciences SESN Sesen Bio TARA Protara Therapeutics MESO Mesoblast Ltd VBLT Vascular Biogenics Ltd EVAX Evaxion Biotech AS RDHL Redhill Biopharma Ltd CELC Celcuity LLC NUVL Nuvalent PYXS Pyxis Oncology ELEV Elevation Oncology CLGN Collplant Biotechnologies Ltd DFFN Diffusion Pharmaceuticals DNTH Dianthus Therapeutics MDAI Spectral AI POAI Predictive Oncology CRVS Corvus Pharmaceuticals FBRX Forte Biosciences IDRA Idera Pharmaceuticals ISR IsoRay HUMA Humacyte MIRM Mirum Pharmaceuticals PRTO Proteon Therapeutics PTE Polarityte RNXT RenovoRx SPNE SeaSpine Holdings Corp ZIOP ZIOPHARM Oncology AEMD Aethlon Medical UNCY Unicycive Therapeutics ASX ASE Industrial Holding Co Ltd ADR CAL Caleres CLDX Celldex Therapeutics ETON Eton Pharmaceuticals FTS Fortis INMB INmune Bio IT Gartner SU Suncor Energy DYAI Dyadic International

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Swayampakula Ramakanth (HC WAINWRIGHT)

Buy Since 15-Jun-2020

8 months 10 days ago
(31-Dec-2025)

7/7 (100%)

$1.82 (43.54%)

548

Ben Haynor (LAKE STREET)

Buy Since 29-Jul-2025

$9.5

$-2.3 (-19.49%)

1 years 1 months 12 days ago
(29-Jul-2025)

1/1 (100%)

$6.21 (188.75%)

154

Show more analysts

Please expand the browser size to see the chart

Which stock is Swayampakula Ramakanth most bullish on?

Potential upside of $59.3 has been obtained for CELC (CELCUITY LLC)

Which stock is Swayampakula Ramakanth most reserved on?

Potential downside of $0.04 has been obtained for NUVL (NUVALENT)

What Year was the first public recommendation made by Swayampakula Ramakanth?

On 2015